251 related articles for article (PubMed ID: 30718503)
1. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; Shon-Nguyen Q; Xiao Y; Ramakrishnan V; Polson AG; Samineni D; Leipold D; Humke EW; McClellan JS; Berdeja JG
Blood Cancer J; 2019 Feb; 9(2):17. PubMed ID: 30718503
[TBL] [Abstract][Full Text] [Related]
2. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Lee HC; Raje NS; Landgren O; Upreti VV; Wang J; Avilion AA; Hu X; Rasmussen E; Ngarmchamnanrith G; Fujii H; Spencer A
Leukemia; 2021 Jan; 35(1):255-258. PubMed ID: 32317775
[No Abstract] [Full Text] [Related]
4. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F; Haeder T; Wartenberg-Demand A; Anderson KC
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):372-380. PubMed ID: 30930134
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
Massard C; Soria JC; Krauss J; Gordon M; Lockhart AC; Rasmussen E; Upreti VV; Patel S; Ngarmchamnanrith G; Henary H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1057-1063. PubMed ID: 30915497
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Vij R; Nath R; Afar DEH; Mateos MV; Berdeja JG; Raab MS; Guenther A; Martínez-López J; Jakubowiak AJ; Leleu X; Weisel K; Wong S; Gulbranson S; Sheridan JP; Reddy A; Paiva B; Singhal A; San-Miguel JF; Moreau P
Clin Cancer Res; 2020 May; 26(10):2308-2317. PubMed ID: 31969330
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H; Sidana S
Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
[TBL] [Abstract][Full Text] [Related]
10. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Camus V; Tilly H
Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
12. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Elkins K; Zheng B; Go M; Slaga D; Du C; Scales SJ; Yu SF; McBride J; de Tute R; Rawstron A; Jack AS; Ebens A; Polson AG
Mol Cancer Ther; 2012 Oct; 11(10):2222-32. PubMed ID: 22807577
[TBL] [Abstract][Full Text] [Related]
13. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
14. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
15. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
[TBL] [Abstract][Full Text] [Related]
16. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
18. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
20. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]